MedPharm Director of Chemistry Dr. Tyrell Towle says the company ultimately hopes to produce an FDA-approved medication to help slow down the progression of Alzheimer's disease, or at least improve its symptoms.
Photo courtesy of MedPharm
Denver Awards MedPharm Medical Marijuana Research and Development License for Alzheimer’s Study
The company will launch a study with 30 participants to determine whether cannabis-based medication improves patients’ symptoms.
MedPharm, a Colorado-based cannabis research and formulation development company, has received a Medical Marijuana Research and Development License from the City of Denver, the last piece in the licensing puzzle for the company’s study on how cannabis-based medication might impact Alzheimer’s disease and other forms of dementia.
MedPharm received a state research license over a year ago, according to the company’s Director of Chemistry Dr. Tyrell Towle, and the local permit now allows the company to launch its research, which will initially be a small study with 30 participants.
MedPharm is working with a local neurologist to recruit dementia patients for the study.
“He’s already introduced the idea to many of them and he’s gotten a positive response,” Towle said. “We’ll be recruiting from his current patient population and, if necessary, we’ll [seek] more patients, more volunteers.”
MedPharm will administer gel capsules that contain both cannabinoids and other natural, non-cannabis-derived compounds that have been shown to have a positive effect on brain health. The company will also distribute a cannabinoid-only formulation, as well as a placebo, to compare how each formulation performs.
“What we’re hoping to see is [that] the cannabinoid-only formulation improves symptoms and blood flow … better than the placebo, and then we’re hoping that the full formulation improves the outcomes of the patients even better than the cannabinoid-only formulation,” Towle said. “That would be the ideal outcome of the study, but we’ll just have to see what happens.”
Photo courtesy of MedPharm
MedPharm received a state research license over a year ago, and the local permit allows the company to launch its study with participating patients.
Over the course of the six-month study, which will launch once all the patients are enrolled within the next month or so, MedPharm will monitor whether the patients’ symptoms are improving—whether they’re sleeping better, eating better or feeling less agitated, for example. The company will conduct regular caregiver surveys to evaluate these symptoms, and it will also use brain scans to monitor blood flow.
“From that, we’re hoping to see increased blood flow to the areas of the brain that are important to Alzheimer’s and dementia, and also see what else is going on,” Towle said. “Maybe there’s increased blood flow in an area of the brain we didn’t anticipate, and we can look at future medical benefits of targeting that.”
MedPharm will also take blood samples and measure them for inflammatory biomarkers that are associated with brain damage.
Once the initial study is complete, the company will determine which form of dementia is best treated with medical cannabis, as well as which dosage form works best. Then, MedPharm hopes to expand the clinical trial to a large enough population to provide statistical significance.
“Ultimately, we hope to get an FDA-approved medication that helps to either slow down the progression of Alzheimer’s disease or at least improve the symptoms,” Towle said. “At the very least, we want to relieve symptoms, but if we can also slow down the progression or prevent the development of the disease, that would be ideal.”
MedPharm has applied with the DEA to obtain a federal license to cultivate cannabis for research, and although the company was notified last year that its application has been selected to advance in the application process, it has yet to receive another update.
Las Vegas, NV (June 22, 2020) – PRESS RELEASE – GFive Cultivation has launched a new signature cannabis line, Pynk Mynk, a collection of strains that delivers an exciting and uplifting experience. Pynk Mynk is a business venture with Harlem hip hop legend, fashion aficionado, entrepreneur and actor, Cam'ron, inspired by his authentic and trendsetting style and music.
Pynk Mynk is a light green in color with pink accents and is saturated in a high production of trichomes. The sativa hybrid boasts a sweet citrusy flavor and spicy woody aroma and offers an energetic feel. It is developed and produced by GFive Cultivation, a minority- and family-owned and operated cannabis cultivation based in Las Vegas, Nev.
Today, in select states, we stand on a new dawn, where one can indulge in cannabis freely, using an app or visiting a dispensary without any criminal issues. For the culture, this is a historical moment to produce a cannabis line that is inspired by Cam’ron, a Harlem recording artist and leader of the iconic rap group The Diplomats. Pynk Mynk is reminiscent of his persona and music.
“For most of my career, cannabis has been an enigmatic part, on one end, something that I enjoy and inspires my creativity; and the other, has caused issues with the law,” exclaims Cam’ron. “GFive Cultivation understands my vision and passion in cultivating my strain. We produced a top-notch and satisfying product.”
“This new business venture is nothing but amazing for us,” states Larry Smith, founder and CEO of GFive Cultivation. “Beyond his music, Cam’ron is entrepreneurial and forward-thinking; and the opportunity to join forces with him to cultivate one of our best lines representing his lifestyle brand is huge for us. Just like Cam’ron, our Pynk Mynk strain will make its impact, globally, and leave its mark among all cannabis enthusiasts. Collaborations with globally recognized artists and tastemakers, within our community are just the beginning, at GFive. We intend to leave our mark within the cannabis industry.”
Pynk Mynk product will be available in customized packages to select licensed dispensaries such as Essence, Jardin, Reef, Silver Sage Wellness and Sahara Wellness in Las Vegas beginning this month. Additional strains produced by GFive Cultivation include: Lemon Gorilla, Zkittles Cake, Kumquat, Gelato and the signature Big Baby Bud in partnership with actor/comedian Darren Brand, currently available at Jardin and Reef dispensaries.
Stephen Canino | Adobe Stock
MedMen Co-Founders Step Down from Company’s Board of Directors
Adam Bierman, a member of the board, and Andrew Modlin, an observer to the board, have resigned from these roles.
MedMen co-founders Adam Bierman and Andrew Modlin have stepped down from the company’s board of directors, according to a June 17 announcement.
Bierman had previously served as a board member, while Modlin served as an observer to the board.
Modlin’s employment agreement with MedMen had already expired last month, according to the announcement.
MedMen also announced June 17 that it has reached a settlement in litigation between MMMG-MC Inc. (BVI), Brent Cox, Omar Mangalji, et al. and various parties in a lawsuit originally filed in Los Angeles Superior Court in January 2019. MedMen denies any wrongdoing, but “believes its contribution to the settlement is in the best interest of its shareholders,” according to the announcement.
MedMen also recently lost its medical cannabis dispensary license in Virginia after the Board of Pharmacy voted to deny the company’s request for an extension and rescinded its conditional license for a retail outlet in Staunton, according to a News Leader report.
olyasolodenko | Adobe Stock
Oregon Cannabis Association Elects New Board of Directors
Twenty-five candidates applied to serve on the board, and 13 were chosen to lead the organization.
Twenty-five candidates applied to serve on the board, and 13 were chosen to lead the organization, which aims to create an inclusive cannabis industry in Oregon.
The OCA’s newly elected board of directors includes:
Molly Conroy, CEO & Co-Founder, Scientia Labs – Conroy received her Bachelor’s in Political Science and Master’s in International Relations, and has worked at multiple trade associations across various industries, predominantly on policy and economic affairs. Conroy previously served as the OCA’s program director, and has held project management and public affairs roles in the regulated cannabis industry.
Heidi Fikstad, Co-Owner & CEO, Moss Crossing Dispensary – Fikstad holds a degree in Design | Media Arts from UCLA and has worked in the cannabis industry for a decade. She served as vice president of Women Leaders in Cannabis for two years and as chapter organizer of Eugene Tokeativity for two years.
Kendra Freeman, Co-Founder, Oso Verde Farms & MENDIa CBD – Freeman managed a large cannabis farm in Humboldt County for nearly a decade before co-founding Oso Verde Farms and MENDIa CBD. She served a one-year term on the OCA board in 2019 and is the committee chair for the Social Justice Committee, which helps facilitate the OCA’s expungement clinics.
Jesce Horton, Co-Founder, Nu Leaf Project & Founder, LOWD & Strattus – Horton, an engineer and horticulturist, has a background in industrial energy efficiency and has been appointed by Oregon Gov. Kate Brown to the Task Force for Cannabis Environmental Best Practice. Horton co-founded the Nu Leaf Project last year alongside his wife, Jeannette Ward Horton, and currently operates a cultivation business, LOWD, with plans to open a dispensary called Strattus. Horton also serves on the Cannabis Conference 2020 advisory board and will speak at Cannabis Conference 2020.
Nathan Howard, Co-Founder, East Fork Cultivars – Howard founded East Fork Cultivars in 2015 with his brother, Aaron, to provide accessible plant-based medicine and expand the genetic diversity of the cannabis plant. He serves on the Human Access Project’s board of directors and is an adviser to Initiative Petition 34, the Psilocybin Service Therapy Initiative. Howard is also a founding member of the Craft Cannabis Alliance and the campaign to create interstate cannabis commerce by the end of 2021.
Anna Kaplan, Co-Founder & CEO, SugarTop Buddery – Kaplan holds a Masters of Fine Arts degree from the Pennsylvania Academy of the Fine Arts and previously worked in restaurant management. She is the current president of Women Leaders in Cannabis, a 501 C-6 nonprofit organization.
Doug Morris, Attorney, Miller Nash – Morris represents cannabis businesses in the Pacific Northwest in business contracts, compliance, disputes, acquisitions and sales. He works with growers, processors, retailers, owners and allied businesses, and serves on the board for Metropolitan Public Defender, SOLVE and Albertina Kerr. His firm supports OCA’s Regional Happy Hours and The Initiative.
Oscar Nelson, Co-Founder, Sweet Relief – Nelson co-founded Sweet Relief, a retail chain of five dispensaries along with a grow facility and hydroponics store in Northwest Oregon.
Hunter Neubauer, Co-Ownder, Oregrown – Neubauer has a background in medical device sales, and is now the co-owner of Oregrown, an Oregon-based cannabis company.
Jesse Peters, Founder & CEO, Mantis Growth Investments – Peters was previously the co-founder and CEO of Eco Firma Farms, an indoor cannabis cultivation facility designed to operate entirely on wind power. He is also a founding member of the OCA, as well as a retired marine, firefighter and national speaker.
Jeremy Pratt, Founder, Nectar – Pratt has been cultivating cannabis for over 25 years, and founded Nectar in 2014.
Catherine Leathers Self, Co-Owner, Self Made Cannabis Company – Leathers Self has been involved in the OCA through lobbying efforts in Salem, D.C., networking events and the Summer Fair. She served on the OCA’s board in 2019, and was an educator before founding Self Made Cannabis Company.
Meghan Walstatter, Co-Owner, Siren Cannabis – Walstatter is a co-owner of Siren Cannabis, an OLCC licensed cultivation operation in Clackamas County. She has been a cultivator for over 17 years, and sold her dispensary, Pure Green, to C21 last year. Walstatter is a founding member of the OCA and has served on advisory committees with the OLCC and the City of Portland.
Maria_Savenko | Adobe Stock
Cannabis Marketing 101: Why Businesses Should Think Before They Text
Knowing and following these rules can help insulate your business from large-scale liability.
Hardly a day goes by without a report of another lawsuit—almost invariably one that claims to be a class action—against another cannabis-related business for allegedly violating the federal Telephone Consumer Protection Act (TCPA), most often through the business’s text-based marketing. Not surprisingly, the bulk of these cases are being filed in jurisdictions such as California, Colorado and Washington where cannabis legalization is broadest. But with an increasing number of states permitting both medicinal and recreational use of cannabis, these cases have been and will be brought throughout the U.S.
With the prospect of uncapped damages awards tied to the number of text messages sent, the TCPA has created a literal cottage industry of plaintiffs’ lawyers. They are eager to capitalize on the missteps of entrepreneurs that are frequently so focused on growing their businesses that they overlook or ignore the legal niceties separating a TCPA-compliant, text-based marketing program from one that can lead to a ruinous financial judgment. Knowing and following all of the rules can help insulate your business from large-scale liability, but the one Golden Rule is quite simple: Think before you text.
What is the TCPA?
The TCPA is a statute passed by Congress in 1991 to combat the perceived scourge of so-called robocalls and unwanted faxes from telemarketers. Fax machines were what passed for cutting-edge technology at the time, while cellphones were in their relative infancy (and about as big as an infant). Owners of cellphones often incurred expensive per-minute charges for all calls, whether incoming or outgoing. Text messaging did not yet exist.
Generally, the TCPA prohibits the making of any call to a cellphone using an automatic telephone dialing system (ATDS) or an artificial or prerecorded voice without the prior express consent of the called party. The TCPA also prohibits the making of any call to a residential landline using an artificial or prerecorded voice without prior express consent. For those who send faxes, the TCPA prohibits sending unsolicited advertisements unless the recipient has an established business relationship with the sender or voluntarily provides their fax number; all faxed advertisements also must contain information allowing the recipient to opt-out of receiving future faxes.
Despite regular efforts of business organizations and other affected groups to amend the TCPA to reflect the sea changes in technology that have occurred in the last three decades, Congress has failed to act, leaving to the Federal Communications Commission (FCC) and the courts the task of interpreting and applying the statute to modern realities. For instance, while there is no indication that lawmakers even contemplated text messaging when the TCPA was passed, the FCC and the courts have agreed that SMS and MMS text messages are the equivalent of a “call” for TCPA purposes, subjecting them to the same rules and restrictions as voice calls.
Likewise, what constitutes an ATDS remains an absolute muddle. Although the TCPA defines an ATDS as equipment with “the capacity … to store or produce telephone numbers to be called, using a random or sequential number generator; and … to dial such numbers,” the FCC and the courts are hopelessly divided as to what this means, leading to a dispute in nearly every TCPA case.
Why should cannabis-related businesses care about the TCPA?
The reason cannabis-related businesses need to care about the TCPA is simple: violating it can be expensive. Very, very expensive. Millions and millions of dollars expensive. Company-threatening expensive.
The TCPA prescribes a penalty ranging from between $500 and $1,500 for each violation of the statute. That’s $500 to $1,500 for each and every call, text or fax that runs afoul of the statute. What’s more, the TCPA contains no cap on the amount of damages that can be awarded, and there have been any number of TCPA verdicts and settlements in the single millions, tens of millions, even hundreds of millions of dollars. For a cannabis-related business that might engage in a modest text-based marketing campaign involving, say, 10,000 messages, getting it wrong could mean potential liability of between $5 million and $15 million. And even though some courts recently have become more receptive to claims that uncapped TCPA liability can be so disproportionate as to violate a company’s fundamental right to due process, there is no guarantee that an offending company can count on a constitutional argument to mitigate the effects of its violation.
Furthermore, many commercial general liability and other business insurance policies explicitly or implicitly exclude coverage for TCPA claims. Not only do cannabis-related businesses that violate the TCPA face the prospect of ruinously large awards, but they often must do so without an insurer to defend or indemnify them in an environment that presents certain unique hurdles to obtain insurance in the first place.
What should cannabis-related businesses do about text-based marketing?
The TCPA legal landscape is ever-shifting, and the only certainty is uncertainty. (Currently, the U.S. Supreme Court is considering a case seeking to throw out the entire TCPA as a violation of the First Amendment right to free speech.) It is impossible for cannabis-related companies to insulate themselves completely from potential liability, especially when so much of their marketing depends on text-based campaigns direct to consumers, whether by the companies themselves or third-party marketers on their behalf. Observing the fundamental rule of thinking before texting, however, can go a long way toward mitigating TCPA risk. To that end:
Always get consent. The key to sending marketing text messages to consumers lies in obtaining prior express written consent. There are many ways to do this, but it is critical that a consumer affirmatively consents to receiving promotional or mixed promotional/informational text messages. Giving consumers the option to “opt out at sign-up,” where subscribers must uncheck a box to opt out of receiving promotional materials, can be riskier than requiring an affirmative check at sign-up, for example.
Keep records of consent up to date. Just as consumers can give consent to receiving text messages, they can revoke their consent in any “reasonable” manner, according to the FCC, although there is no precise definition of what is considered “reasonable.” Cannabis-related businesses must have a process in place to capture and implement revocations of consent. Regularly scrub databases against the National Do-Not-Call Registry. And be mindful of reassigned cellphone numbers; TCPA liability can apply to calls/texts to the holder of a reassigned number even if the previous holder of the number gave their express consent.
Do not blindly rely on third-party marketers. Cannabis-related businesses that outsource their text-based campaigns to third-party marketers may still be liable for TCPA violations for texts sent on their behalf. Carefully vet the third-party marketer and its practices, including insurance; verify their own practices for obtaining consumer consent; insist on adequate and enforceable indemnification.
Check insurance coverage. While often excluded under standard business insurance policies, coverage for TCPA-related claims is available. Cannabis-related businesses should check with their brokers. If a company intends to engage in text-based marketing, the cost of TCPA coverage may be well worth it.
The TCPA presents a huge pitfall for unwary companies, and cannabis-related businesses are no exception. Indeed, as plaintiffs’ lawyers have set their sights on the burgeoning cannabis industry, it is more important than ever to be guard against becoming the next target. When it comes to marketing to consumers, cannabis-related businesses are well advised to think before they text.
Joshua Hornis a partner and co-chair of the Cannabis Law Practice at Fox Rothschild LLP and is nationally ranked by Chambers USA as a leading lawyer in cannabis law. He leads a national team that serves the needs of businesses in the legalized cannabis and hemp sector on employment, licensing, banking, real estate and corporate financing and other services for emerging and established businesses. He can be reached at jhorn@foxrothschild.com.
Jerry Arth is a partner in the Litigation Department at Fox Rothschild LLP. He handles complex commercial litigation on behalf of both plaintiffs and defendants and is a thought leader on a variety of topics including class action defense, TCPA and electronic discovery. He can be reached at garth@foxrothschild.com.
Legislative Map
Cannabis Business Times’ interactive legislative map is another tool to help cultivators quickly navigate state cannabis laws and find news relevant to their markets. View More